ArticleMaterials today. Bio2025
Nanoliposome-sericin hydrogel microneedle patches effectively alleviate inflammation and scavenge ROS for the treatment of CKD-aP.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- β-Sitosterol from Camellia oil integrated photothermal liposomes increasing redox-balanced anti-inflammation in macrophages.Journal of the science of food and agriculture · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Kidney Disease-associated Pruritus (CKD-aP) is a debilitating condition commonly observed in patients with chronic kidney disease (CKD), characterized by severe skin itching and inflammation. Despite the availability of oral medications and topical treatments, their efficacy is limited, and systemic side effects are a significant concern. This study presents the development of a novel microneedle system (Cap@Lip/Dife-MNs), designed to address CKD-aP through targeted and sustained drug delivery. The system integrates liposome-encapsulated capsaicin, known for its anti-inflammatory and analgesic effects, with methacryloyl sericin (SerMA) hydrogel-loaded Difelikefalin, a drug that modulates neural transmission and immune responses. Liposomes enhance the solubility and stability of capsaicin, while the SerMA hydrogel provides sustained release of Difelikefalin. The Cap@Lip/Dife-MNs system demonstrates excellent drug delivery capabilities, promoting skin cell proliferation, reducing oxidative stress, and alleviating pruritus by modulating neural signaling pathways. In vivo transcriptomic analysis revealed significant modulation of immune-related genes and reduction of oxidative stress markers, confirming its immune-regulatory and anti-inflammatory effects. Moreover, neural signal analysis showed reduced pruritus-related transmission, emphasizing its potential as a non-invasive, effective treatment for CKD-aP. These findings highlight the Cap@Lip/Dife-MNs microneedle system as a promising therapeutic platform for CKD-aP, with strong potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.